PRINTED: 05/24/2021 FORM APPROVED OMB NO. 0938-0391

	R MEDICARE & MEDIC				OMB NO. 0938-0391	
STATEMENT OF DEFICIENCIES AND PLAN OF CORRECTION		X1) PROVIDER/SUPPLIER/CLIA	(X2) MULTIPLE C		(X3) DATE SURVEY COMPLETED	
		IDENTIFICATION NUMBER:	A. BUILDING	00		
		15G300	B. WING		04/23/2021	
NAME OF	PROVIDER OR SUPPLIEI	R		ADDRESS, CITY, STATE, ZIP CODE		
				PIKE ST		
TRANSI	TIONAL SERVICES	S SUB LLC	MARTI	NSVILLE, IN 46151		
(X4) ID	SUMMARY S	STATEMENT OF DEFICIENCIES	ID	PROVIDER'S PLAN OF CORRECTION	(X5)	
PREFIX	1	NCY MUST BE PRECEDED BY FULL	PREFIX	(EACH CORRECTIVE ACTION SHOULD BE CROSS-REFERENCED TO THE APPROPRIATION OF THE APPROPRIATION	COMPLETION	
TAG	REGULATORY OR LSC IDENTIFYING INFORMATION)		TAG	DEFICIENCY)	DATE	
W 0000						
DIda 00						
Bldg. 00	This visit was for the Post Certification Revisit (PCR) to the investigation of complaint #IN00347983 and the Covid-19 focused infection control survey completed on 3/9/21. Complaint #IN00347983: Corrected.		W 0000			
			W 0000			
	Unrelated deficience	ey cited.				
	Survey dates: April	1 22 and 23, 2021				
	Facility Number: 0	00819				
	Provider Number: 15G300					
	AIM Number: 100249100					
		o reflects state findings in				
	accordance with 46					
		this report completed by				
	#15068 on 5/3/21.					
W 0368	483.460(k)(1)					
	DRUG ADMINIST	FRATION				
Bldg. 00	_	ug administration must				
	assure that all drugs are administered in					
	compliance with the physician's orders.					
	Based on record review and interview for 1 of 3		W 0368	All staff in the home will be	05/23/2021	
	clients in the sample (B) and two additional			retraine to follow Medication		
	clients (D and G), the facility failed to ensure			Administration procedures and		
	staff administered the clients' medications as			ensuring all medications are		
	ordered.			administered per Physicians Orders.		
	Findings include:			Supervisory observations will b completed weekly for one mont		
	On 4/22/21 at 12:30	6 PM, a review of the		two times per month for one	<i>'</i>	
		eports was conducted and		month and then at least monthl	y	
		wing medication errors with		ongoing to monitor medications	-	
	no adverse reaction			are administered as ordered.		

LABORATORY DIRECTOR'S OR PROVIDER/SUPPLIER REPRESENTATIVE'S SIGNATURE

TITLE

(X6) DATE

Any defiency statement ending with an asterisk (*) denotes a deficency which the institution may be excused from correcting providing it is determined that other safegaurds provide sufficient protection to the patients. (see instructions.) Except for nursing homes, the findings stated above are disclosable 90 days following the date of survey whether or not a plan of correction is provided. For nursing homes, the above findings and plans of correction are disclosable 14 days following the date these documents are made available to the facility. If deficiencies are cited, an approved plan of correction is requisite to continued program participation.

DEPARTMENT OF HEALTH AND HUMAN SERVICES CENTERS FOR MEDICARE & MEDICAID SERVICES

PRINTED: 05/24/2021 FORM APPROVED OMB NO. 0938-0391

STATEMENT OF DEFICIENCIES X1) PROVIDER/SUPPLIER/CLIA AND PLAN OF CORRECTION IDENTIFICATION NUMBER: 15G300		A. B	(X2) MULTIPLE CONSTRUCTION A. BUILDING B. WING		(X3) DATE SURVEY COMPLETED 04/23/2021			
NAME OF PROVIDER OR SUPPLIER TRANSITIONAL SERVICES SUB LLC			STREET ADDRESS, CITY, STATE, ZIP CODE 110 W PIKE ST MARTINSVILLE, IN 46151					
(X4) ID PREFIX TAG	SUMMARY STATEMENT OF DEFICIENCIES (EACH DEFICIENCY MUST BE PRECEDED BY FULL REGULATORY OR LSC IDENTIFYING INFORMATION)		ID PREFIX PREFIX (EACH CORRECTIVE ACTION SHOULD CROSS-REFERENCED TO THE APPRO DEFICIENCY)		E	(X5) COMPLETION DATE		
	1) On 3/7/21 at 8:00 AM, client G did not receive Olanzapine (antipsychotic). 2) On 3/7/21 at 12:00 PM, client B did not receive Lactulose (constipation). 3) On 3/17/21 at 8:00 PM, client D did not receive Naltrexone, Guanfacine (attention deficit hyperactivity disorder), Vraylar (oppositional defiant disorder) and Cetirizine (antihistamine). 4) On 3/28/21 at 8:00 PM, client D did not receive Naltrexone, Guanfacine, Vraylar and Cetirizine. On 4/22/21 at 12:50 PM, the Area Director indicated the clients' medications should be administered as ordered. 9-3-6(a)			Persons Responsible: Prog Supervisor, Program Directo Nurse				

FORM CMS-2567(02-99) Previous Versions Obsolete

Event ID:

QS9312

Facility ID: 000819

If continuation sheet Page 2 of 2